Targets › GASTRIN
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Aug 2027.
Open in Phaseline: the race on GASTRIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Gastrin 17 (GAST-17) Gastrin-17 receptor agonist | GASTRIN | Phase 2 | Type 1 Diabetes Mellitus | Aug 2027 |
Type 1 Diabetes Mellitus (1)
mixed (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.